Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Showing posts with label retreatment. Show all posts
Showing posts with label retreatment. Show all posts

Friday, October 9, 2015

What the Heck are RAVs? —Alan Franciscus, Editor-in-Chief

RAVs are resistance associated variants.  RAVs occur during (viral breakthrough) and after treatment (relapse) with direct acting antiviral medications (inhibitors—protease, polymerase, NS5A).  In other words, someone is treated and not cured.
 
This can lead to a particular class of drugs (protease, polymerase, NS5A inhibitors) not working as well because a person has developed drug resistance.
 
In clinical trials of the direct acting antiviral medications, approximately 1% to 7% of the trial participants were not cured.  In real world settings it is likely higher because of many issues such as missed doses, LIFE, and various health and other issues not addressed in clinical trials.  
 
In this month’s Snapshots, I wrote about a couple of studies that addressed re-treatment.  To overcome the RAVs and other negative predictors of treatment response (previous treatment non-response, cirrhosis, etc.,) ribavirin was added to both re-treatment groups.  As a result, 75%-100% of the patients were cured.  There are drugs being developed that have a high barrier to resistance that will replace ribavirin.  Thankfully we have ribavirin now to help people in need of re-treatment and cure and, importantly, to prevent further hepatitis C disease progression.
 
The approach to retreatment of RAVs is rapidly evolving.  Some physicians are beginning to test for RAVs, but it is far from being a routine test.  Talk with your medical provider if you have questions.

If you are being re-treated with a direct acting antiviral medication, it is important to find an expert to consult with about the best HCV treatment regime for you.